Beijing SL Pharmaceutical Co., Ltd. (SZSE: 002038)
Health Care · Biotechnology · CN
CN¥7.08
+17.22% today · -13.1% 1Y
Beijing SL Pharmaceutical Co., Ltd. (SZSE: 002038) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.08B and employs 901 people.
Over the last twelve months the share price has lost 13.1%, trading between 4.81 and 9.40.
Tweenvest scores Beijing SL Pharmaceutical Co., Ltd. across four factors: quality 69/100, value 65/100, growth 16/100, dividend 47/100. Its strongest factor is quality.
002038 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.08B
- Revenue (TTM)
- $85.77M
- P/E
- —
- EPS
- -0.48
- Dividend yield
- 0.14%
- Beta (5Y)
- -0.17
- 52-week high
- CN¥9.40
- 52-week low
- CN¥4.81
- Avg volume (3M)
- —
- Shares outstanding
- 1.03B
- Employees
- 901
- Next earnings
- —
About Beijing SL Pharmaceutical Co., Ltd.
Operating both domestically within the People's Republic of China and across international markets, Beijing SL Pharmaceutical Co., Ltd. is a biopharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of genetic engineering-based pharmaceuticals and associated medicinal products. Its extensive portfolio of finished pharmaceutical products encompasses a diverse range of medications, including but not limited to, temozolomide, arsenic trioxide, lenalidomide, docetaxel, paclitaxel, recombinant human granulocyte colony-stimulating factor (filgrastim), recombinant human interleukin-11, recombinant human interleukin-2, thymopentin, vinorelbine bitartrate, hydroxyl-camptothecine, nimustine hydrochloride, asparaginase, PEG L-asparaginase, calcium foliate, recombinant human basic fibroblast growth factor, ciclosporin, mycophenolate mofetil dispersible, ornidazole, adefovir dipivoxil, levofloxacin hydrochloride, azithromycin, ribavirin, tenofovir disoproxil fumarate, valacylovir hydrochloride, lysozyme, stavudine, tropisetron hydrochloride, granisetron hydrochloride, omeprazole, ademetionine 1,4-butanedisulfonate, glutathione, enoxaparin sodium, coenzyme complex, ginkgo biloba extract, simvastatin, telmisartan, naftopidil, nicergoline, zaleplon, cytidine disodium triphosphate, febuxostat, risedronate sodium, loratadine dispersible, somatostatin, octreotide acetate, calcitonin (salmon), the combination of paracetamol and tramadol hydrochloride, and etodolac. Furthermore, the company supplies active pharmaceutical ingredients (APIs). Established in Beijing, People's Republic of China, in 1994, the enterprise initially operated under the name Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd. before officially adopting its current designation, Beijing SL Pharmaceutical Co., Ltd., in 1998.
- ISIN
- CNE000001L31
- Founded
- 1994
- Listed since
- Sep 9, 2004
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.45 | -0.57% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.67 | +0.31% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.57 | -0.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.80 | -0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $824.34 | -1.16% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.35 | -5.33% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.